Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell- mediated graft-versus-host disease

Transplantation

Volumn 66, Issue 9, 1998, Pages 1220-1229

  Blazar, Bruce R ^a,b   Taylor, Patricia A ^b   Panoskaltsis Mortari, Angela ^b   Narula, Satwant K ^c   Smith, Sidney R ^c   Roncarolo, Maria G ^d   Vallera, Daniel A ^e  

^a Box 109UMHC ^*  (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^e UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 10;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032533769     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199811150-00018     Document Type: Article

References (37)

1. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease prevention. Immunol Rev 1997; 157: 79.
2. De Wit D, Van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 361.
3. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988; 140: 4245.
4. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12: A49.
5. 8+ lymphoid engraftment. J Immunol 1994; 152: 1004.
6. + donor T cells fail to induce experimental acute graft- versus-host disease. J Immunol 1995; 155: 585.
7. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250: 830.
8. Vieira P, de Waal-Malefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991; 88: 1172.
9. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444.
10. Roncarolo MG. The role of interleukin-10 in transplantation and GVHD. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-host disease. New York: Marcel Dekker, 1997: 693.
11. Howard M, O'Garra A, Ishida H, de Waal Malefyt R, de Vries J. Biological properties of interleukin 10. J Clin Immunol 1992; 12: 239.
12. Bejarano MT, de Waal Malefyt R, Abrams JS, et al. Interleukin-10 inhibits allogeneic proliferation and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992; 4: 1389.
13. + T-cell clones and T cells: specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754.
14. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
15. Hancock W, Mottram PL, Purcell LJ, Han WR, Pietersz GA, McKenzie IF. Prolonged survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is associated with selective intragraft cytokine protein expression: interleukin (IL)-4 and IL-10 but not IL-2 or interferon-gamma. Transplant Proc 1993; 25: 2937.
16. Abramowicz D, Durez P, Gerard C, et al. Neonatal induction of transplantation tolerance in mice is associated with in vivo expression of IL-4 and -10 mRNAs. Transplant Proc 1993; 25: 312.
17. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493.
18. Bacchetta R, Parkman R, McMahon M, et al. Dysfunctional cytokine production by host-reactive T-cell clones isolated from a chimeric severe combined immunodeficiency patient transplanted with haploidentical bone marrow. Blood 1995; 85: 1944.
19. Go NF, Castle BE, Barrett R, et al. Interleukin-10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990; 172: 1625.
20. DeFrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992; 175: 671.
21. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990; 145: 4167.
22. Suda T, O'Garra A, MacNeil I, Fischer M, Bond M, Zlotnik A. Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. Cell Immunol 1990; 129: 288.
23. Chen W-F, Zlotnik A. IL-10, a novel T cell cytotoxic differentiation factor. J Immunol 1990; 147: 528.
24. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex (MHC) disparate donor grafts. Blood 1995; 85: 842.
25. 8+ T cells. J Immunol 1996; 157: 3250.
26. Mantel N. Evaluation of survival data in two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 50: 163.
27. Gorczynski RM, Wojcik D. A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1, and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion. J Immunol 1994; 152: 2011.
28. Garlisi CG, Pennline KJ, Smith SR, Siegel MI, Umland SP. Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol Immunol 1993; 30:669.
29. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 1993; 23: 333.
30. 8+ T cells. J Immunol 1995; 155: 2396.
31. Baker KS, Allen RD, Roths JB, Sidman CL. Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease. Bone Marrow Transplant 1995; 15: 595.
32. Williamson E, Garside P, Bradley JA, More IA, Mowat AM. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 1997; 159: 1208.
33. Krenger W, Snyder K, Smith S, Ferrara JL. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251.
34. Emmanouilides CE, Luo J, Baldwin G, et al. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro. Bone Marrow Transplant 1996; 18: 369.
35. Smith SR, Terminelli C, Pennline KJ, Kenworthy-Bott L, Donkin J, Calzetta A. Inhibitory effects of recombinant human interleukin 10 on disease manifestations in a P→F1 model of acute graft versus host disease. Transplantation 1995; 59: 890.
36. Holler E, Ertl B, Hintermeier-Knabe R, et al. Inflammatory reactions induced by pretransplant conditioning: an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Leuk Lymphoma 1997; 25: 217.
37. Hempel L, Korholz D, Nussbaum P, Bonig H, Burdach S, Zintl F. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 365.